Form 4: Amphastar Pharmaceuticals Executive Acquires Shares and Options

Yakob Liawatidewi, EVP Corp Admin Center at Amphastar Pharmaceuticals, reports acquisition of shares and options.

Summary

• Yakob Liawatidewi, an executive at Amphastar Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• The report indicates the acquisition of 20,837 shares of common stock represented by restricted stock units (RSUs) that vest in four equal annual installments starting March 10, 2026.
• Additionally, Liawatidewi acquired options to purchase 44,253 shares of common stock at an exercise price of $28.41, vesting in four equal annual installments beginning March 10, 2026.
• Following these transactions, Liawatidewi directly owns 93,671 shares and indirectly owns 2,459 shares through the Yakob and Sunmoon Trust.
• Liawatidewi also directly owns options for 44,253 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by an executive is generally a good sign, but it's a routine transaction.

Positives

• The acquisition of shares and options by an executive could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules for the RSUs and options suggest a multi-year commitment from the executive.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding insider transactions. They are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment.

Key Dates